

# DRUG UTILIZATION REVIEW BOARD MEETING AGENDA

January 20, 2021  
MO HealthNet

[Join Webex Meeting](#)

Meeting number (access code): 133 956 5049

Join from a video system or application

Dial [1339565049@stateofmo.webex.com](tel:1339565049)

You can also dial 173.243.2.68 and enter your meeting number.

Tap to join from a mobile device (attendees only)

[650-479-3207](tel:6504793207) Call-in toll number (US/Canada)

[\\* Click HERE for Meeting Documents \\*](#)

10:00 – 10:05	Welcome, Announcements and Introductions	Chairperson
10:05 – 10:15	Minutes Review	Discussion/Approval
10:15 – 10:25	Pharmacy Program/ Budget Update	Elizabeth Short
10:25 – 10:35	Review of Prior Authorization Meeting and Public Hearing	Josh Moore
	<b>Old Business</b>	
10:35 – 10:45	Implementation Schedule – Criteria for Previously Approved Clinical Edits, Step Therapies and PA's	Josh Moore
	<b>New Business</b>	
10:45 – 11:00	Proposed Actions - New Drug/Product Review (See Website and Attached Summary) <ul style="list-style-type: none"><li>i. Open Access</li><li>ii. Clinical Edit/Step Therapy</li><li>iii. PDL Agents</li><li>iv. Prior Authorization</li></ul>	Josh Moore
11:00 – 11:45	<b>Clinical and Fiscal Edits</b> <u>Existing Criteria</u> <ul style="list-style-type: none"><li>i. 15 Day Supply – Oral Oncology Fiscal Edit</li><li>ii. Acetaminophen Cumulative Dose Clinical Edit</li><li>iii. BiDil Clinical Edit</li><li>iv. Butalbital Combinations Excessive Therapy Edit</li><li>v. Butalbital Combinations without Codeine Clinical Edit</li><li>vi. Corlanor Clinical Edit</li><li>vii. Entresto Clinical Edit</li><li>viii. Selzentry Clinical Edit</li></ul> <u>New Criteria or Revision of Existing Criteria</u> <ul style="list-style-type: none"><li>i. 15 Day Supply Fiscal Edit</li><li>ii. Antipsychotics – 1<sup>st</sup> Generation (Typical) Clinical Edit</li><li>iii. Antipsychotics – 2<sup>nd</sup> Generation (Atypical) Clinical Edit and Reference List</li><li>iv. Benzodiazepines (Select Oral) Clinical Edit</li><li>v. Biosimilar vs Reference Products Fiscal Edit</li></ul>	Josh Moore

- vi. CAR T-Cell Therapy Clinical Edit
- vii. Diabetic Supply Quantity Limit Fiscal Edit
- viii. Duchenne Muscular Dystrophy (DMD) Clinical Edit
- ix. High Cost Medication Kits Fiscal Edit
- x. High Risk Therapies Clinical Edit – *NEW*
- xi. Isturisa Clinical Edit – *NEW*
- xii. Morphine Milligram Equivalent Accumulation Clinical Edit
- xiii. Neuromyelitis Optica Spectrum Disorder (NMOSD) Clinical Edit – *NEW*
- xiv. Non-Oral Contraceptives Fiscal Edit
- xv. Opioids – Short-Acting Combinations Clinical Edit
- xvi. Opioids – Short-Acting Single Agents Clinical Edit
- xvii. Out-of-State, Non-Bordering Pharmacies Fiscal Edit - *NEW*
- xviii. Psychotropic Medications Polypharmacy Clinical Edit
- xix. PrEP Fiscal Edit
- xx. Spinal Muscular Atrophy (SMA) Clinical Edit – *NEW*
- xxi. Transmucosal Immediate Release Fentanyl (TIRF) Clinical Edit

11:45 – 1:00

**Preferred Drug List (PDL)**

Josh Moore

Existing Criteria

- i. Alzheimer’s Agents
- ii. Antiandrogenic Agents
- iii. Antiemetic, 5-HT<sub>3</sub>, NK1 and Other Select Agents, Non-Injectable
- iv. Antiemetic, THC Derivatives
- v. Anti-Parkinsonism MAO-B Inhibitor Agents
- vi. Hereditary Angioedema Agents
- vii. Opiate Emergency Reversal Agents

New Criteria or Revision of Existing Criteria

- i. Anticonvulsants, Dravet Syndrome – *NEW*
- ii. Antiemetic, 5-HT<sub>3</sub> and NK1 Agents, Injectable
- iii. Anti-Migraine, Alternative Oral Agents
- iv. Anti-Migraine, Serotonin (5-HT<sub>1</sub>) Receptor Agonists
- v. Antiretrovirals, Treatment Products (*Reference List*)
- vi. Anti-Parkinsonism Non-Ergot Dopamine Agonists
- vii. Calcitonin Gene-Related Peptide (CGRP) Inhibitors
- viii. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors – *NEW*
- ix. Fibromyalgia Agents
- x. GI Motility Agents
- xi. Glucagon Agents
- xii. Neuropathic Pain Agents
- xiii. NSAID Agents
- xiv. Opiate Dependence Agents
- xv. Opioids, Long Acting
- xvi. Sedative Hypnotic Agents
- xvii. Skeletal Muscle Relaxants
- xviii. Somatostatic Agents – *NEW*
- xix. Tramadol-Like Agents
- xx. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors – *NEW*

- 1:00 – 1:15      **LUNCH**
- 1:15 – 1:30      **Program Utilization Information – Conduent Update**      Jennifer Colozza
- i.      Call Center Statistics
  - ii.     CyberAccess User Statistics
  - iii.    New Drug Statistics
  - iv.    “Top 25” Drugs by Cost/Claims
- 1:30 – 1:50      **Other Business**

*Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, Agenda may move more quickly.*

**NEXT MEETING: April 21, 2021**  
Meeting via Webex unless  
otherwise specified